Claudia Henschke, MD

Dr. Claudia Henschke has achieved international acclaim as an innovator in thoracic radiology and as a crusader for the early detection of lung cancer, particularly among populations with previous asbestos exposure. As a principal investigator and driving force behind the development of low-dose computed tomography (CT) screening protocols, Henschke’s work has transformed cancer detection and prevention, dramatically improving prognosis for countless patients.

Starting her career during a time when lung cancer was often diagnosed far too late for effective intervention, Henschke championed the use of low-dose CT as a screening tool for high-risk groups. Her studies provided the evidence base needed to push for policy changes, including expanded access to regular screenings for workers in industries with known asbestos hazards. Through clinical trials and longitudinal research, she demonstrated that early identification of tumors dramatically increases survival rates and reduces the burden on healthcare systems.

Dr. Henschke has authored hundreds of peer-reviewed articles, delivered keynote lectures at global conferences, and advised government agencies on occupational health policy. Her leadership roles within major medical societies and international collaborations reflect a commitment to multidisciplinary approaches, integrating radiological advances with epidemiology, patient care, and public health education.

Beyond her technical contributions, Henschke is recognized for her mentorship of young physicians and researchers. She is an advocate for health equity, ensuring that screening technologies reach vulnerable and underserved populations, including former industrial workers, firefighters, and teachers. Her body of work stands as a cornerstone for comprehensive, science-based responses to the continued threat of asbestos-related cancers.